



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No. : 4,808,614

CERTIFICATE

Issued

: February 28, 1989

On an Application of: Larry W. Hertel

AUG 0 8 1989

Serial No.

: 058,219

Filed

: June 4, 1987

of correction

Entitled

: Difluoro Antivirals and Intermediate

Therefor

Docket No.

: X-5707B

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. 1.322

Commissioner of Patents and Trademarks

Washington, D. C. 20231

Sir:

を変え

The patentee of the above-identified patent respectfully request that you issue a Certificate of Correction to correct errors which occurred during the printing of the patent. Attached are two copies of Form PTO 1050 on which the errors are specified.

Eli Lilly and Company Patent Division/JAJ Lilly Corporate Center Indianapolis, Indiana 46285 Respectfully submitted,

Attorney for Patentee Registration No. 26,472

Phone: 317-276-5183

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. :

4,808,614

Page 2 of 2

DATED

February 28, 1989

INVENTOR(S):

Larry W. Hertel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 16, line 52 insert -- 16 ml -- after "in"

Signed and Sealed this
Twentieth Day of February, 1990

Attest:

JEFFREY M. SAMUELS

Attesting Officer

Acting Commissioner of Patents and Trademarks

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,614

Page 1 of 2

DATED : February 28, 1989

INVENTOR(S) : Larry W. Hertel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2, line 47 "R" in the structure should read -- =0 --

Column 3, line 8 should be a new paragraph.

Column 4, line 3 should read -- 1-[4-amino-5-(2-chlorovinyl)-2-oxo-lH-pyrimidin-1-yl]-2-desoxy-2,2-difluororibose

Column 10, line 61 "CDC13" should read -- CDC13 --

Column 14, line 21, "s, 1)" should read -- (s, 1H) --

Column 14, line 33 "thanesulfonyloxytri" should read -- thanesulfonyloxytrimethylsilane --

Column 14, line 52 "CD₃OD, 90MH₂) 6" should read -- (CD₃OD, 90MH₂) δ ---

Column 15, line 17 "-2,2-difluorori (CD₃OD ..." should read -- -2,2-difluororibose. nmr (CD₃OD ... --

Column 16, line 37 "MH_Z) δ 3.72-4.34 (s,4H)" should read -- MH_Z) δ 3.72-4.34 (m,4H), 4.78 (s,4H) --

Column 16, in line 44 delete the figure 6.

Column 16, line 45, insert after "(d," -- J=8 Hz, 1H), 6.3 --

Staple Herr) Only 1

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,614

DATED : February 28, 1989

INVENTOR(S): Larry W. Hertel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2, line 47 "R" in the structure should read -- =0 -

Column 3, line 8 should be a new paragraph.

Column 4, line 3 should read -- 1-[4-amino-5-(2-chloroviny1) 2-oxo-1H-pyrimidin-1-y1]-2-desoxy-2,2-difluoropibose

Column 10, line 61 "CDC13" should read -- GDC13 --

Colymn 14, line 21, "s, 1)" should read -- (s,1H) --

Column 14, line 33 "thanesulfonyloxytri" should read thanesulfonyloxytrimethylsilane --

Column 14, line 52 "CD3OD, 90MH_z) 6" should read -- (CD3OD, 90MH_z) δ --

Column 15, line 17 "-2,2-difluorori (CD3OD ..." should read -2,2-difluororibose. nmr (CD3OD ... --

Column 16, line 37 $^{\rm "MH}_{\rm Z}$) 63.72-4.34 (s,4H) $^{\rm "}$ should read - MH $_{\rm Z}$) 63.72-4.34 (m,4H), 4.78 (s,4H) --

Column 16, in line 44 delete the figure 6.

Column 16, line 45, insert after "(d," -- J=8 Hz, 1H), 6.3

Column 16, line 52 insert -- 16 ml -- after "in"

MAILING ADDRESS OF SENDER:

Eli Lilly and Company Corporate Center Indianapolis, Indiana 46285 PATENT NO. 4,808,614

No. of add'l. copies @ 30∢ per page

ح/>

FORM PTO 1050 (REV. 3-82)